High-throughput screening for small molecule drug discovery

High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery. In this whitepaper, “Disrupting Drug Discovery From Assay Development to Lead Compound”, SAMDI Tech CSO, Zack Gurard-Levin, discusses the important aspects to consider when choosing the right methodology for drug discovery.

The whitepaper covers traditional label-dependent approaches versus novel label-free technologies; how researchers determine which methodology offers the most promising path forward for their target; how to take into account assay sensitivity, data quality, costs, and speed; and when to outsource to contract research organisations with an established discovery infrastructure to lead hit identification and hit-to-lead programs.

Download the whitepaper here.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free